N-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide,methanesulfonic acid structure
|
Common Name | N-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide,methanesulfonic acid | ||
|---|---|---|---|---|
| CAS Number | 1246203-36-0 | Molecular Weight | 684.735 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C27H34F2N8O7S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
| Name | N-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide,methanesulfonic acid |
|---|---|
| Synonym | More Synonyms |
| Molecular Formula | C27H34F2N8O7S2 |
|---|---|
| Molecular Weight | 684.735 |
| Exact Mass | 684.195984 |
| PSA | 198.73000 |
| LogP | 4.76720 |
|
~%
N-[4-[4-[2-(dif... CAS#:1246203-36-0 |
| Literature: Pathway Therapeutics Limited Patent: US2010/249099 A1, 2010 ; Location in patent: Page/Page column 83 ; US 20100249099 A1 |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| Ethanesulfonamide, N-[4-[4-[2-(difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)-, methanesulfonate (1:1) |
| N-{4-[4-[2-(difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl}-2-(dimethylamino)ethanesulfonamide methanesulfonate |
| N-(4-{4-[2-(Difluoromethyl)-4-methoxy-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl}phenyl)-2-(dimethylamino)ethanesulfonamide methanesulfonate (1:1) |
| N-(4-(4-(2-(difluoromethyl)-4-methoxy-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-2-(dimethylamino)ethanesulfonamide methanesulfonate |